With plenty of data from the CheckMat-227 trial to go through, one expert breaks down the vital data that will directly impact the practice.
At the European Society of Medical Oncology 2019 Congress results for the CheckMate-227 trial were presented and discussed among a number of oncologists from across the globe.
Oncology Nursing News’® sister publication OncLive® had the chance to sit down with Marina Garassino, MD, chief of the thoracic oncology division at the National Cancer Institute in Milan, Italy, to discuss the data from the trial and how it will impact practices going forward.
What we know is that there are patients that do not benefit from a single agent alone and also a single agent, but still we are unable to identify them. At the time we are unable to identify patients who can be harmed by the combination of ENTPD4, ENTPD1, and also single agent.
I think that we have to discuss with the patients because maybe chemotherapy plus immunotherapy is better because we avoid the crossing of the curves. Other patients may be PD-L1 negative, TMB-I, or they can be the right population to be treated with a combination.